NO20070906L - Fremgangsmate for behandling av hyperfosfatanemi ved anvendelse av lantanhydroksykarbonat - Google Patents

Fremgangsmate for behandling av hyperfosfatanemi ved anvendelse av lantanhydroksykarbonat

Info

Publication number
NO20070906L
NO20070906L NO20070906A NO20070906A NO20070906L NO 20070906 L NO20070906 L NO 20070906L NO 20070906 A NO20070906 A NO 20070906A NO 20070906 A NO20070906 A NO 20070906A NO 20070906 L NO20070906 L NO 20070906L
Authority
NO
Norway
Prior art keywords
hyperphosphate
anemia
treating
lanthanum hydroxycarbonate
ckd
Prior art date
Application number
NO20070906A
Other languages
English (en)
Norwegian (no)
Inventor
Josephine Christine Ferdinando
David Gilmour
Original Assignee
Shire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Pharmaceuticals Inc filed Critical Shire Pharmaceuticals Inc
Publication of NO20070906L publication Critical patent/NO20070906L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20070906A 2004-07-27 2007-02-16 Fremgangsmate for behandling av hyperfosfatanemi ved anvendelse av lantanhydroksykarbonat NO20070906L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59110504P 2004-07-27 2004-07-27
PCT/US2005/026668 WO2006015055A1 (fr) 2004-07-27 2005-07-27 Methode pour traiter l'hyperphosphatemie au moyen d'hydroxycarbonate de lanthane

Publications (1)

Publication Number Publication Date
NO20070906L true NO20070906L (no) 2007-04-23

Family

ID=35787449

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070906A NO20070906L (no) 2004-07-27 2007-02-16 Fremgangsmate for behandling av hyperfosfatanemi ved anvendelse av lantanhydroksykarbonat

Country Status (14)

Country Link
US (1) US20060153932A1 (fr)
EP (1) EP1708723A4 (fr)
JP (1) JP4869229B2 (fr)
KR (2) KR101072196B1 (fr)
CN (1) CN101018555A (fr)
AU (1) AU2005269362B2 (fr)
BR (1) BRPI0513603A (fr)
CA (1) CA2574450C (fr)
EA (1) EA010980B1 (fr)
MX (1) MX2007001114A (fr)
NO (1) NO20070906L (fr)
NZ (1) NZ552861A (fr)
WO (1) WO2006015055A1 (fr)
ZA (1) ZA200701707B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
SI2172205T1 (sl) * 2003-08-26 2014-10-30 Shire Biopharmaceuticals Holdings Ireland Limited Farmacevtska formulacija obsegajoča lantanove spojine
CA2583548A1 (fr) * 2004-10-15 2006-04-27 Altairnano, Inc. Liant phosphate a prise de comprimes reduite
WO2007022445A2 (fr) * 2005-08-17 2007-02-22 Altairnano, Inc. Compositions et methodes de traitement de l'insuffisance renale chronique et d'autres etats chez des animaux domestiques
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
WO2007089577A2 (fr) * 2006-01-30 2007-08-09 Globoasia, Llc Méthode permettant d'inverser, de prévenir, de retarder ou de stabiliser la calcification des tissus mous
ATE530896T1 (de) * 2006-05-05 2011-11-15 Shire Int Licensing Bv Assay für lanthan-hydroxycarbonat
US20070259052A1 (en) * 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
CA2798081C (fr) * 2010-05-12 2024-02-13 Spectrum Pharmaceuticals, Inc. Hydroxyde de carbonate de lanthane, oxycarbonate de lanthane, et procedes pour leur fabrication et methodes pour leur utilisation
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
US8263119B2 (en) * 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
GB201501000D0 (en) * 2015-01-21 2015-03-04 Univ Edinburgh Lanthanum thiosulfate and methods of preparation of the same
US20190381024A1 (en) * 2015-10-27 2019-12-19 Medice Arzneimittel Putter Gmbh & Co. Kg Nicotinamide for lowering phosphate levels in hyperphosphatemia
KR101880447B1 (ko) * 2015-12-01 2018-07-23 김배용 생리활성물질 복합체, 이의 제조방법 및 이를 포함한 화장료 조성물
KR101684289B1 (ko) 2016-05-17 2016-12-09 한국식품연구원 락토바실러스 sp. KCCM 11826P 균주를 이용한 고인산혈증 예방, 만성 신장질환 치료용 약학조성물 및 건강기능성 식품
US10322409B1 (en) * 2018-03-05 2019-06-18 King Fahd University Of Petroleum And Minerals Low temperature hydrothermal method for the preparation of LaCO3OH nanoparticles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4592082A (en) * 1984-08-10 1986-05-27 The United States Of America As Represented By The United States Department Of Energy Quantitative determination of mineral composition by powder X-ray diffraction
CA2117351C (fr) * 1992-01-13 1998-03-03 Julian Belknap Lo Methode de fabrication permettant d'accroitre la durete des comprimes
CA2128199C (fr) * 1994-07-15 1997-02-04 Bernard Charles Sherman Compositions pharmaceutiques, solides, stables, renfermant du maleate d'enalapril
US5435986A (en) * 1994-08-30 1995-07-25 Industrial Technology Research Institute Method for preparing high purity aluminum hydroxide
GB9506126D0 (en) * 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
CA2381713A1 (fr) * 1999-09-02 2001-03-08 Big Bear Bio, Inc. Procedes et compositions servant a limiter les niveaux de phosphate serique
US6160016A (en) * 1999-12-22 2000-12-12 Wisconsin Alumni Research Foundation Phosphorus binder
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
WO2002085348A1 (fr) * 2001-04-23 2002-10-31 Anormed Inc. Utilisation de composes des terres rares pour la prevention de calculs renaux
US7469036B2 (en) * 2002-04-19 2008-12-23 Los Alamos National Security, Llc Analysis of macromolecules, ligands and macromolecule-ligand complexes
AU2003229437A1 (en) * 2002-05-08 2003-11-11 Shire Holding Ag Use of lanthanum for the treatment of hypercalcemia and bone metastasis
US20040161474A1 (en) 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
SI2172205T1 (sl) * 2003-08-26 2014-10-30 Shire Biopharmaceuticals Holdings Ireland Limited Farmacevtska formulacija obsegajoča lantanove spojine
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions

Also Published As

Publication number Publication date
CA2574450A1 (fr) 2006-02-09
NZ552861A (en) 2010-11-26
JP4869229B2 (ja) 2012-02-08
KR20070054191A (ko) 2007-05-28
KR101072196B1 (ko) 2011-10-10
AU2005269362A1 (en) 2006-02-09
CA2574450C (fr) 2011-07-19
BRPI0513603A (pt) 2008-05-13
EA010980B1 (ru) 2008-12-30
JP2008508297A (ja) 2008-03-21
KR20090023743A (ko) 2009-03-05
EA200700273A1 (ru) 2007-08-31
WO2006015055A1 (fr) 2006-02-09
CN101018555A (zh) 2007-08-15
EP1708723A1 (fr) 2006-10-11
EP1708723A4 (fr) 2006-12-20
AU2005269362B2 (en) 2010-08-12
ZA200701707B (en) 2008-10-29
MX2007001114A (es) 2007-07-11
US20060153932A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
NO20070906L (no) Fremgangsmate for behandling av hyperfosfatanemi ved anvendelse av lantanhydroksykarbonat
NO20075821L (no) Fremgangsmate til a oke testosteron- og beslektede steroidkonsentrasjoner hos kvinner
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
NO20082536L (no) Behandling av kronisk nyresykdom(CKD)individer ved bruk av lantanforbindelser
EA201101187A1 (ru) Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
NO20061074L (no) Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet
NO20074509L (no) Kombinasjon av organiske forbindelser
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
NO20074824L (no) Forlengelse av tid til sykdomsprogresjon eller overlevelse hos kreftpasienter
MY154984A (en) Preventing autoimmune disease
NO20064964L (no) Behandling av svekket respiratorisk funksjon
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
ECSP10010266A (es) Antagonistas del receptor mineralcorticoide no esteroidal derivado de 6h-dibenzo[b,e]oxepina
TW200740452A (en) Therapeutic gastrodia extracts
Pyo et al. Factors related to blood glucose control in patients with diabetes
WO2009066299A3 (fr) Utilisation du génotypage de l'haptoglobine dans le diagnostic et le traitement d'une maladie cardiovasculaire
NO20070127L (no) Fremgangsmate for behandling av granuloma annulare eller sarkoid
NO20093592L (no) Medikament for behandling av diabetes
WO2009132082A3 (fr) Compositions immunogènes contenant des céramides et leurs méthodes d’utilisation
WO2021074786A3 (fr) Compositions non hémolytiques et procédés d'utilisation pour la guérison d'une maladie provoquant des constituants toxiques dans le sang
WO2005089489A3 (fr) Utilisation de la relaxine pour augmenter la compliance arterielle
NO20091659L (no) Fremgangsmater for behandling av disruptive oppforselsforstyrrelser
Wadden et al. LIRAGLUTIDE 3.0 mg AS AN ADJUNCT TO INTENSIVE BEHAVIOR THERAPY IN INDIVIDUALS WITH OBESITY: SCALE IBT 56-WEEK RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL
Yuan et al. Predictive role of child-to-adult blood pressure trajectories for incident metabolic syndrome: 30-year Hanzhong adolescent hypertension study
Teppo et al. Oral anticoagulant therapy and risk of admission to long-term care in patients with atrial fibrillation: a nationwide cohort study

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application